Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
221 hedge funds and large institutions have $2.38B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 88 increasing their positions, 65 reducing their positions, and 41 closing their positions.
57% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $10.6M
35% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 65
5% less funds holding
Funds holding: 233 → 221 (-12)
19% less capital invested
Capital invested by funds: $2.95B → $2.38B (-$572M)
24% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 41
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$25.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$24.9M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$23.6M |
| 4 |
Morgan Stanley
New York
|
+$16.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$28.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$27.8M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$26.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$22.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.8M |
MRTX Hedge Fund Activity: Q1 2023 in Review
221 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2023, worth a combined $2.38B — down 19% from $2.95B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of MRTX and 31 opened new positions — a net loss of 10 holders — while 65 trimmed existing stakes and 88 added.
The largest buyer was BlackRock, adding an estimated $25.8M. The largest seller was Ameriprise, exiting entirely with an estimated $28.9M sold.
- 221 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2023, down from 233 in Q4 2022.
- Funds reported $2.38B of Mirati Therapeutics, Inc. Common Stock stock for Q1 2023, down 19% quarter-over-quarter.
- 31 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2023 and 41 closed out, a net change of -10 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2023 was BlackRock, an estimated $25.8M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2023 was Ameriprise, an estimated $28.9M sold.
Based on aggregated 13F filings for Q1 2023.